Using technology to improve care for pancreatic cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The IMPACT project aims to establish a data-sharing infrastructure among expert centers for pancreatic surgery to enhance the quality of care for patients with pancreatic cancer. This observational study will collect pseudonymized clinical and imaging data from patients who have undergone diagnostic procedures and treatments for pancreatic lesions. The data will be utilized to train and validate artificial intelligence tools that can potentially improve patient outcomes. A project steering committee will oversee the management and sharing of the collected data among participating centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years of age
* Patients who received diagnostic procedures and/or treatment for (suspected) benign and malignant pancreatic lesions as registered in the Dutch Pancreatic Cancer Project (PACAP) audit database and healthy individuals who received an abdominal CT-scan (controls)

Exclusion Criteria:

\- Subjects who object to the use of their data for the purpose of scientific research

Where it's running

• Regional Academic Cancer Center Utrecht
  Utrecht, Netherlands Recruiting

Study contacts

• Study coordinator: Lois A Daamen, MD, PhD
• Email: l.a.daamen-3@umcutrecht.nl
• Phone: +31651223276

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for pancreatic cysts at UCSF

  This study is setting up a registry to track patients with pancreatic cysts to see how these cysts change over time and to help doctors make better treatment decisions.

  Recruiting University of California, San Francisco · San Francisco, California · NCT04291651

• Developing a blood test for early diagnosis of pancreatic cancer

  This study is trying to develop a simple blood test to help find pancreatic cancer early and track how well treatments are working for patients.

  Recruiting at 8 sites Memorial Sloan Kettering Cancer Center · Middletown, New Jersey and 12 other locations · NCT03334708

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.